Prosecution Insights
Last updated: October 02, 2026
Application No. 17/796,487

A METHOD FOR DETERMINING AN ORDER IN WHICH A FOOD PRODUCT IS CULTURED

Final Rejection §103§112
Filed
Jul 29, 2022
Priority
Jan 30, 2020 — EU 20154681.9 +1 more
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
DSM IP Assets B.V.
OA Round
3 (Final)
61%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
556 granted / 914 resolved
+0.8% vs TC avg
Strong +31% interview lift
Without
With
+31.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
37 currently pending
Career history
954
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
36.5%
-3.5% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 914 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on July 30, 2026 has been entered. Claims 15 and 17 – 35 are pending; claim 27 is withdrawn; claims 15, 17 – 26 and 28 – 35 have been considered on the merits. All arguments have been fully considered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 29 and 35 remain rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 29 and 35 remain/is indefinite for reciting “providers” as the term is not adequately defined by the claim language or specification. Clarification is required. Response to Arguments Applicant indicates the term is defined by the specification; however, the specification fails to define the term. While the specification recites “a food producer may use bacterial cultures coming from two or more providers, such as for instance bacterial culture providers,” this is not a definition of the term such that the scope of the claim may be clearly defined and understood by one practicing the claimed method. Moreover, the term remains indefinite as it may change over time and is not a common term in the art limiting to any particular scope. In this regard, the scope of the phrases, therefor claims, remain indefinite. Claim Rejections - 35 USC § 103 Previous rejections under 35 U.S.C. 103 as being unpatentable over Klaenhammer et al. (US 5593885) in view of Marcó et al. (2012) are withdrawn. Applicant’s arguments are persuasive, particularly in that while the prior art substitutes one strain with a second strain within a single fermentation is not the same process, the prior art does not teach collecting a process sample during culturing with each bacteria of the first subset and exposing the second subset to the first in order to determine bacteriophage sensitivities. No steps of collection and exposing are disclosed or suggested, but rather rotates the various cultures with successive fermentations. Double Patenting Previous rejections on the ground of nonstatutory double patenting are withdrawn due to applicant's filing of a proper Terminal Disclaimer on July 30, 2026. Allowable Subject Matter Claims 15, 17 – 26, 28, 30 – 34 are allowed. Conclusion All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Jul 29, 2022
Application Filed
Nov 04, 2025
Non-Final Rejection mailed — §103, §112
Feb 25, 2026
Response Filed
May 01, 2026
Final Rejection mailed — §103, §112
Jul 30, 2026
Request for Continued Examination
Jul 31, 2026
Response after Non-Final Action
Aug 19, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12714734
TREATEMENT OF PATHOGEN INFECTIONS FORMULATIONS AND METHODS FOR USE
3y 10m to grant Granted Aug 25, 2026
Patent 12714741
METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE
3y 3m to grant Granted Aug 25, 2026
Patent 12709732
USE OF HYALURONIC ACID OR SALT THEREOF AND/OR TREHALOSE IN STABILIZING ERGOTHIONEINE, AND ERGOTHIONEINE COMPOSITION CONTAINING HYALURONIC ACID OR SALT THEREOF AND/OR TREHALOSE
3y 3m to grant Granted Aug 18, 2026
Patent 12692488
CHIMERIC LYSOZYME VARIANT AND APPLICATION THEREOF IN ANIMAL FEED ADDITIVE
3y 2m to grant Granted Jul 28, 2026
Patent 12685754
METHOD OF FIXATING AND STABILIZING NITRIC OXIDE METABOLITES THROUGH FERMENTATION OF NITROGEN-CONTAINING NATURAL SUBSTANCE
4y 2m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+31.1%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 914 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month